chris@arsenalvp.com
Karuna Therapeutics, a biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, has raised $89.2 million for its IPO after pricing its over 5.5 million shares at $16 per share. The stock began trading June 28, 2019 on the NASDAQ under the ticker symbol "KRTX." Goldman Sachs and Citigroup are the lead underwriters. Karuna's pre-IPO backers included ARCH Venture Partners, Fidelity Management & Research Co, Eventide Asset Management, Pivotal bioVenture Partners, Partner Fund Management, Wellcome Trust, Sands Capital and Alexandria Venture Investments.
New York City and Berlin-based 3Box, a provider of decentralized identity and data storage infrastructure, has secured $2.5 million in seed financing. Placeholder Ventures led the round with participation from Venrock, Northzone and CoinFund.
Cambridge, Massachusetts-based Vaxess Technologies, a biotechnology company, has closed its Series A funding round at $8.2 million. The Engine led the round.
Surterra Wellness, a health and wellness companies, has raised $100 million in Series D funding. The investors included former Patrón Spirits Company CEO Ed Brown.
San Francisco-based Degreed, a workforce learning and skill-tracking platform, has raised $35 million in funding. The investors were Owl Ventures, Jump Capital, Signal Peak Ventures GSV Accelerate and AllianceBernstein Growth Stage Capital. Degreed also closed a $40 million venture debt facility with AllianceBernstein.
Picosun, a Finnish manufacturer of ALD equipment, has secured 12 million euros in funding. The investors included CapMan Growth fund, Finnish Industry Investment Oy and First Fellow Partners.
Puls, which operates a network of service providers and technicians, has named Mitch Galbraith as CEO and a member of its board of directors. Previously, he was executive vice president and general manager of j2 Global's gaming and entertainment division. Puls' backers include Sequoia Capital, Temasek, Viola and Samsung Next.
Silicon Valley-based Fungible, a provider of data-centric computing, has secured $200 million in Series C financing. SoftBank Vision Fund led the round with participation from other investors that included Norwest Venture Partners.
Cambridge, Massachusetts-based Ultivue, a provider of tissue biomarker identification and quantification assays for translational and pathology research labs, has secured $22 million in Series C funding. Northpond Ventures led the round with participation from other investors that included ARCH Venture Partners, 6 Dimensions Capital, Yonghua Capital and Applied Ventures.
Lincoln, Nebraska-based Opendorse, an athlete marketing platform, has secured $3.125 million in funding. Previous backers Serra Ventures and Flyover Capital led the round.